title: Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients.
abstract: We evaluated the safety and efficacy of intrapericardial bevacizumab (BEV) for treating symptomatic malignant pericardiac effusion (MPCE) in seven advanced cancer patients. All patients had previously undergone multiple lines of systemic therapy. Each patient received paracentesis and intrapericardial infusions of 100 or 200 mg of BEV every two weeks. Systemic treatments for primary tumors continued for all patients during BEV treatment. Of the seven patients, three achieved a complete response, two achieved a partial response, and two showed no response with regard to MPCE after BEV infusion. The median overall survival time was 168 days (range, 22-224 days). In six of the seven patients, effusion did not recur before death. Toxicity associated with BEV treatment was mild and manageable in all patients. This study provides preliminary evidence that intrapericardial BEV may be an effective and safe treatment for MPCE in patients with advanced cancers.
authors.affiliation: Weifang Medical University, Weifang, China.|Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Dawei
authors.initials: D
authors.lastname: Chen
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Shi
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhu
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.
authors.forename: Minghuan
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Department of Radiation Oncology, Changzhou Cancer Hospital, Soochow University, Changzhou, China
authors.forename: Judong
authors.initials: J
authors.lastname: Luo
authors.affiliation: Department of Clinical Laboratory, Mengyin People's Hospital, Linyi, China.
authors.forename: Kaijun
authors.initials: K
authors.lastname: Chen
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.
authors.forename: Li
authors.initials: L
authors.lastname: Kong
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China.|Shandong Academy of Medical Sciences, Jinan, China.
authors.forename: Jinming
authors.initials: J
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D010490:Pericardial Effusion / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000068258:Bevacizumab
keywords: advanced cancer; bevacizumab; intrapericardial; malignant pericardial effusion